Adverse metabolic disorders during highly active antiretroviral treatments (HAART) of HIV disease.
about
Antisense-mediated inhibition of human immunodeficiency virus (HIV) replication by use of an HIV type 1-based vector results in severely attenuated mutants incapable of developing resistanceEffect of rosiglitazone and metformin on insulin resistance in patients infected with human immunodeficiency virus receiving highly active antiretroviral therapy containing protease inhibitor: randomized prospective controlled clinical trialEffects of the human immunodeficiency virus-protease inhibitor, ritonavir, on basal and catecholamine-stimulated lipolysisFirst-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial.Selective inhibition of DNA replicase assembly by a non-natural nucleotide: exploiting the structural diversity of ATP-binding sitesLeptin and Adiponectin in the HIV Associated Metabolic Syndrome: Physiologic and Therapeutic Implications.The effect of Spirulina platensis versus soybean on insulin resistance in HIV-infected patients: a randomized pilot study.Opportunistic Infections among People Living with HIV (PLHIV) with Diabetes Mellitus (DM) Attending a Tertiary Care Hospital in Coastal City of South IndiaThe Molecular Signature of HIV-1-Associated Lipomatosis Reveals Differential Involvement of Brown and Beige/Brite Adipocyte Cell LineagesHIV protease inhibitors block the zinc metalloproteinase ZMPSTE24 and lead to an accumulation of prelamin A in cells.Viability of primary osteoblasts after treatment with tenofovir alafenamide: Lack of cytotoxicity at clinically relevant drug concentrations.Current use of statins reduces risk of HIV rebound on suppressive HAARTA potent HIV protease inhibitor, darunavir, does not inhibit ZMPSTE24 or lead to an accumulation of farnesyl-prelamin A in cells.Enhanced antibody responses elicited by a CpG adjuvant do not improve the protective effect of an aldrithiol-2-inactivated simian immunodeficiency virus therapeutic AIDS vaccine.Protease inhibitors used in the treatment of HIV+ induce beta-cell apoptosis via the mitochondrial pathway and compromise insulin secretion.Computational design of antiviral RNA interference strategies that resist human immunodeficiency virus escape.Severe, demyelinating leukoencephalopathy in AIDS patients on antiretroviral therapy.Relationship between combination antiretroviral therapy regimens and diabetes mellitus-related comorbidities among HIV patients in Gaborone Botswana.
P2860
Q24564647-94A26A39-52A5-4517-957D-52C0464C40A7Q24645513-BE6C78C9-A8E9-4C9C-8422-1BCBC8F678C0Q34312147-E08D7C95-8B0D-45C2-A502-8C2BCBD69BD8Q35034306-FDE02EA2-1F5C-444D-BF13-3A1470495E28Q35203594-4774782D-C481-4A31-AAC4-2E10482E0BBAQ35239494-09DCD7BC-0445-4AFE-8AE1-BA23C43664E8Q35671049-4390A642-3B0D-415D-867B-F5686D64F651Q35750218-F736697C-CAF7-4D28-BAED-E51EE8092C41Q35754572-5C044B0D-C041-47BA-A854-0ADD517CAFA7Q35941280-F36B6B9E-6617-47D7-BD03-180BCED85D07Q36275141-1EC73D58-2D33-4DB8-B182-1B64074AE9EFQ36294013-6ED36E5E-3245-474B-8F10-816BB473B33DQ36741508-2213F82A-880A-4634-A05C-E01975A68D94Q37156717-C3C712D1-8D0F-4740-8E82-AB79E1AEFB72Q37162243-CE4B10A2-0FE8-4161-9177-D12A810591E3Q40454547-655AF86B-844F-4B17-9BF1-936BA057C19AQ42807041-36D7FFD6-EFD3-4F4A-B6A4-64809450778EQ52598234-53C7F713-9141-446E-ADF1-CE69D1EF8F3E
P2860
Adverse metabolic disorders during highly active antiretroviral treatments (HAART) of HIV disease.
description
1999 nî lūn-bûn
@nan
1999 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Adverse metabolic disorders du ...... tments (HAART) of HIV disease.
@ast
Adverse metabolic disorders du ...... tments (HAART) of HIV disease.
@en
type
label
Adverse metabolic disorders du ...... tments (HAART) of HIV disease.
@ast
Adverse metabolic disorders du ...... tments (HAART) of HIV disease.
@en
prefLabel
Adverse metabolic disorders du ...... tments (HAART) of HIV disease.
@ast
Adverse metabolic disorders du ...... tments (HAART) of HIV disease.
@en
P2093
P1476
Adverse metabolic disorders du ...... tments (HAART) of HIV disease.
@en
P2093
Gharakhanian S
Rozenbaum W
Vigouroux C
P304
P577
1999-11-01T00:00:00Z